FDA approves cosibelimab-ipdl
On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.).
Related Articles
Pembrolizumab Improves Upon THP in HER2+ Breast Cancer
Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.
FDA Greenlights Cosibelimab in Metastatic or Locally Advanced CSCC
Cosibelimab is now FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not eligible for curative…
Certain Breast Cancer Patients Can Safely Skip Chest Wall Irradiation, Data Suggest
Chest wall irradiation after mastectomy did not improve 10-year overall survival in patients with intermediate-risk breast cancer.
Home | ATTR Revealed
ATTR amyloidosis (ATTR) is a progressive disease, which means it can worsen over time. Early diagnosis is crucial, talk with your doctor today.
ctDNA: ZEST Trial Cleans Up Breast Cancer Treatment – Niraparib (ZEJULA) vs. Placebo in High-Risk TNBC and BRCA-Mutated Patients
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.
Conventional chemotherapy: millions of cures, unresolved therapeutic index
Nature Reviews Cancer – Conventional chemotherapy has successfully cured millions of patients with cancer, yet the mechanisms of action for this remain unclear. In this…
PDX models for functional precision oncology and discovery science
Nature Reviews Cancer – Patient-derived xenograft (PDX) models are valuable surrogates for drug testing in precision oncology. In this Review, Welm and colleagues outline the…
KRAS Cancer Connect to: Dr. Colin Lindsay | KRAS Kickers
The latest advances in KRAS cancer treatments with Dr. Lindsay, a Clinical Senior Lecturer in Medical Oncology at the Christie NHS Foundation Trust moderated by…
Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer
Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.
Cancer Research Early Career Award | Cancer Research | American Association for Cancer Research
Cancer Research Early Career Award | Cancer Research | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none;…
